View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 13, 2020

Eli Lilly to study baricitinib for Covid-19 treatment

Eli Lilly has announced plans to conduct a clinical trial of rheumatoid arthritis drug baricitinib (Olumiant) for the treatment of patients with Covid-19.

The company signed an agreement with the National Institutes of Health (NIH)’s National Institute of Allergy and Infectious Diseases (NIAID) to add a baricitinib arm in NIAID’s Adaptive COVID-19 Treatment Trial.

Read the full article here

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU